◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral WATCH-LIST MEDIUM

ISRIB

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST MEDIUM

For Dylan specifically, ISRIB is a mechanism-aligned candidate for subconcussive-impact memory protection (preclinical TBI data is striking and replicated), but A-tier evidence is animal-only, the only human pharma development path (Calico/AbbVie fosigotifator analog) failed in 2025 ALS Phase 2/3 and the partnership ended November 2025, research-chem identity/purity carries vendor risk, and chronic dosing has a real (not theoretical-only) ubiquitin-proteasome-system concern published 2024. Would upgrade to STRONG-CANDIDATE if (a) Dylan takes a documented concussion and wants an aggressive recovery stack, or (b) a CNS-penetrant successor (DNL343 / next-gen eIF2B activator) gets cleaner human safety data, or (c) Cerebrolysin + V4/V5 baseline is locked and he wants one experimental brain-protection layer on top with informed-consent risk acceptance.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload, daily subconcussive impact (Dylan-archetype)
    WATCH-LIST

    - The TBI-memory-restoration mechanism is the most aligned compound to Dylan's MMA subconcussive thesis that exists. But: he has no detectable cognitive deficit, A-tier evidence is animal-only, the lead human program just failed, and the chronic UPS concern is non-trivial. Cerebrolysin + V4 baseline already covers the brain-protection thesis with much better evidence. Defensible 2-4 week research-chem trial after baseline bloodwork + first Cerebrolysin cycle complete and a clean cognitive baseline established. Not a daily-driver. Not a first-line layer. Reserved tool for (a) post-concussion recovery, or (b) deliberate cautious experiment after Cerebrolysin baseline locked.

  • 30-50, executive maintenance
    WATCH-LIST

    - Mechanism interesting; evidence preclinical only; UPS concern weighs more in older brain. Wait for next-gen eIF2B activator (DNL343 or successor) with cleaner human safety data.

  • 50+, mild cognitive decline
    WATCH-LIST

    - This is the population where the aging-cognitive-decline mouse data is most relevant. *But* it's also the population where chronic-ISR-suppression UPS concerns matter most (aggregation-prone protein load is highest). Net unclear; pharma program failed; recommend waiting. Mechanism-aligned alternatives with better evidence: NAD+ precursors, exercise, Cerebrolysin cycles, sleep optimization.

  • Recovery from documented TBI / concussion
    STRONG-CANDIDATE

    (research-chem path). - Highest-value indication. Mechanism + animal evidence + post-injury timing is exactly what Chou 2017 and Sherman 2022 modeled. 14-28 day cycle paired with Cerebrolysin is the strongest mechanistic neuro-recovery stack accessible without human-trial-grade evidence. Worth the research-chem risk if injury is real and significant.

  • Anxiety-prone
    SKIP-FOR-NOW

    - No mechanism for anxiety; preclinical depression-like behavior data exists but not relevant target. Unnecessary novel-compound exposure.

  • High athletic load, tested status (WADA)
    WATCH-LIST

    - Not on WADA Prohibited List (small molecule, not a peptide hormone). Verify status before each cycle as eIF2B activators get more attention. Same risk-benefit as Dylan-archetype; no special edge for tested athletes.

  • Sleep-disordered
    SKIP-FOR-NOW

    - No sleep mechanism; not a sleep tool.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    post-TBI; SKIP for non-CNS recovery.

  • Strength / anabolic-focused
    SKIP-PERMANENT

    (wrong tool).

▸ Subjective experience (deep)

For research-chem ISRIB at vendor-typical doses (2.5-10 mg oral or intranasal daily, 1-4 week cycles):

  • Most users: nothing clearly detectable. Subtle, if anything — possibly slightly cleaner cognition, easier word retrieval, less mental friction. Easily confused with placebo.
  • A minority report: Mild "lifting of fog," better recall, more sustained focus on cognitive work. Onset typically days 3-7, building gradually. No stim-like surge, no mood elevation.
  • Almost nobody reports: Acute side effects, sleep disruption, anxiety, mood changes. The compound is subjectively non-perturbing.
  • Most informative use case: Someone with documented post-concussion / mild TBI cognitive symptoms reports a more noticeable lifting of those symptoms after 1-2 weeks. This pattern-matches the mouse data (rescue from a pathological state) better than the healthy-baseline experience.

Honest read for Dylan: If he runs ISRIB at baseline (no detectable cognitive deficit), expect to feel nothing or near-nothing. The compound's mouse-model effect is rescue from chronic ISR activation; if he doesn't have the pathological state, he doesn't have the substrate for ISRIB to reverse. If he ever takes a real concussion and runs it post-injury, expectations are more meaningfully positive — though still preclinical-extrapolated.

Set expectation: ISRIB is not modafinil. It's not even Cerebrolysin in the cycle-peak sense. The case for using it is mechanistic and preclinical, not subjective.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown in humans. In mouse studies, cognitive benefit persists after dosing stops (weeks-month durability) — opposite of stim tolerance. No receptor-downregulation logic at play (it's not a receptor agonist).
  • Recommended cycle (community convention): 1-4 weeks on, 4+ weeks off. The post-treatment durable benefit in mice supports this rhythm — pulse, then let it ride.
  • Reset protocol: None needed. Compound clears within 1-2 days (8 h half-life). Cellular eIF2B state returns to baseline; downstream plasticity changes persist on neuron-relevant timescale.
▸ Stacking deep dive

Synergistic with

  • cerebrolysin — Strong theoretical synergy. Cerebrolysin provides BDNF/NGF-mimetic neurotrophic surge that needs protein synthesis machinery to act on. ISRIB unblocks the protein synthesis machinery from chronic ISR repression. Mechanistically convergent at the post-translational-recovery layer. Best stack candidate post-concussion: ISRIB 14-28 d + Cerebrolysin 5 mL IM × 14 d concurrent. Zero direct evidence for the stack — pure mechanism-based reasoning.
  • NAC (already in V4) — Glutathione precursor reduces oxidative stress upstream of ISR sensors (PERK, GCN2). Reducing the input load complements ISRIB's downstream block. Already in Dylan's stack.
  • curcumin (already in V4) — NF-κB and inflammation suppression; reduces neuroinflammatory drivers of chronic ISR. Already in Dylan's stack.
  • omega-3 / DHA (already in V4) — Membrane integrity, anti-inflammatory; supports the post-ISR-block plasticity machinery. Already in Dylan's stack.
  • bpc-157 — BBB integrity, angiogenesis, and tissue-repair pathways; complementary layer to ISRIB's translation-restoration effect. Mechanistically non-overlapping. No direct combo data.
  • dihexa — BDNF / HGF amplification + synaptogenesis. ISRIB unblocks translation, dihexa drives synapse formation. Mechanism-stacked, no direct combo data.
  • semax / NASA / adamax — BDNF-mimetic intranasal peptides. Provide neurotrophic input that ISR-blocked translation suppresses; ISRIB removes the block. Mechanism-stacked.
  • TAK-653 — AMPA-PAM driving glutamatergic plasticity; ISRIB supplies the protein synthesis substrate for plasticity. Speculative synergy, no combo data.

Avoid stacking with

  • PERK inhibitors (GSK2606414 etc.), Sephin1, salubrinal, other ISR-axis modulators — Mechanism stacking on a single pathway, unstudied, unpredictable.
  • Active investigational eIF2B drugs (DNL343, Denali; or remnants of fosigotifator program) — Same target class, redundant + unpredictable.
  • High doses of psychedelics — Theoretical only: psychedelics induce robust stress-granule / ISR signaling in some models; combining with ISR suppression has unknown effect on neuroplasticity outcomes from psychedelics. Speculative.

Neutral / safe co-administration

  • All V4 daily core (NAC, citicoline, magnesium, fish oil, PS, curcumin, rhodiola, theanine, D3+K2, beta-alanine, vitamin C, glycine/tryptophan) — no documented interaction
  • Modafinil — no documented interaction; PK studies on fosigotifator showed clean DDI profile
  • Caffeine, creatine — no concern
  • BPC-157, TB-500, Selank — Russian peptide stack, no overlap
  • Cerebrolysin — see Synergistic above
▸ Drug interactions deep dive
  • CYP enzymes: Fosigotifator (analog) showed no significant DDI with rosuvastatin (OATP/BCRP substrate) or digoxin (P-gp substrate) at tested clinical doses, and well-tolerated alongside CYP3A4 substrates. For ISRIB itself: not formally characterized in humans. Conservative assumption: low DDI risk based on analog data.
  • Hormonal contraceptives: Not characterized; conservative assumption no interaction (small molecule, low CYP3A4 induction signal in analog data). Not relevant to Dylan.
  • Anticoagulants: No data; no mechanism predicting interaction.
  • Alcohol: No data; Dylan zero-baseline, non-issue.
  • MAOIs / SSRIs: No serotonergic mechanism; no expected interaction.
  • Stimulants (modafinil, amphetamines): No documented interaction at fosigotifator analog level.
▸ Pharmacogenomics
  • Minimal data. No specific pharmacogenomic profile for ISRIB.
  • Indirect relevance:
    • eIF2B subunit mutations (EIF2B1-5): Pathogenic mutations cause Vanishing White Matter disease — these patients are the target population for the analog fosigotifator. Healthy carriers of mild variants might respond differently to ISRIB; no data.
    • BDNF Val66Met (rs6265): Met carriers have reduced activity-dependent BDNF release. Theoretical: if reduced endogenous BDNF input drives compensatory ISR / translation compensation, ISRIB might have differential effect by genotype. Speculation. Worth checking on Dylan's 23andMe results.
    • APOE ε4: Increases dementia risk and ISR activation in aged brains. Long-term ISRIB use in ε4 carriers is the subgroup where UPS / aggregation concerns weigh heaviest. Not directly relevant for Dylan's age 20 prophylactic case but worth noting on his 23andMe pull.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem (research grade) Cayman Chemical (caymanchem.com, CAS 1597403-47-8, item 16258) ~$60-150 / 5-25 mg pack typical (est.) high (research-grade gold standard) ≥95% purity by HPLC. Sells trans-ISRIB explicitly. RUO label, requires institution / will sell to individuals depending on jurisdiction. Reference standard for identity verification.
Research-chem (research grade) Tocris Bioscience (trans-ISRIB #5284) similar tier, $80-200 / 10-25 mg high High-purity research compound. RUO label.
Research-chem (research grade) MedChemExpress, Selleck Chemicals, GlpBio, Cell Signaling Technology, Bertin $50-200 / 5-25 mg high Established research-supply vendors; HPLC purity COA standard.
Nootropic-vendor (gray-market consumer-facing) Kimera Chems (kimerachems.co) $56.99-66.99 for 2 g powder or 60 caps × 25 mg (1.5 g total) medium (community vouched on COA practices for some compounds) Markets directly to nootropic consumers. COA images on product page. Powder + dry-fill capsule format. Strict RUO / not for human consumption disclaimer. Best price-per-gram ratio of any vendor; identity verification still wise.
Nootropic-vendor Amino USA (aminousa.com) $40-100 per 500 mg pack typical medium Nootropic-direct. COA practice variable.
Nootropic-vendor PEN Peptide USA, DTSPharmacy, Advanced Research Chemicals (isrib.shop) $60-150 / 10-30 mg packs medium-low Marketing-heavy. Verify COA, third-party HPLC if possible. Variable lot purity reported.

Cost math for a 4-week trial at 5 mg/day:

  • Total dose: 5 mg × 28 d = 140 mg
  • Kimera 2 g powder ($60) covers ~14 cycles at 5 mg/day for 28 d each — extreme overstock
  • More realistic: 1 cycle costs $5-10 in compound at Kimera prices; the rest of any "ISRIB cycle expenditure" is buffer / spare for a second trial / vendor identity-test redundancy

Sourcing strategy for Dylan if he ever runs a cycle:

  1. Order from two independent vendors — one Kimera (consumer-facing, lower cost) + one Cayman/Tocris (research-grade reference).
  2. Visually compare powders. Both should be white-to-off-white crystalline solid.
  3. Optionally: send a few mg from each to a third-party analytical lab (Janoshik, AnalytechX, or a research lab if available) for HPLC-MS confirmation. ~$50-100 per sample. For a compound with no human safety record, this is wise.
  4. Use the research-grade reference as the trial source if the consumer vendor checks out — confirms quality matches.
  5. Keep all packaging, COAs, and lot numbers on file.

Quality verification on receipt:

  • White-to-off-white crystalline solid (both isomers). Yellow / brown / oily appearance = reject.
  • Solubility test: small portion in DMSO should fully dissolve; in water it should not (poor aqueous solubility is a property fingerprint).
  • COA should specify trans- isomer (cis- is significantly less active); ≥95% HPLC purity.
  • CAS 1597403-47-8 (trans-ISRIB) is the active form; CAS 548470-11-7 sometimes appears for the racemate / cis form — read the COA carefully.
▸ Biomarkers to track (deep)

Baseline (before any trial)

  • Cognitive battery: CNS Vital Signs or Cambridge Brain Sciences — establish executive function, working memory, processing speed. Repeat pre/post cycle.
  • Serum NfL (neurofilament light) + GFAP — gold-standard axonal-injury and astroglial-injury biomarkers. Quanterix Simoa platform. Critical for any post-concussion use case; useful baseline for Dylan even without trial.
  • hsCRP, IL-6, ESR — systemic inflammation context (already planned in V4 bloodwork June 2026).
  • CBC, CMP, lipid panel — baseline organ function (already planned).
  • 23andMe pull (already ordered): BDNF Val66Met, COMT, APOE, eIF2B subunit variants if reported.

During use

  • Day 1, 3, 7, 14, 21, 28: subjective effect log — cognition, sleep, mood, training quality, recovery, GI, infection-like symptoms, any neurologic symptom.
  • Mid-cycle (day 14): repeat hsCRP if budget permits — track inflammation trajectory.
  • Adverse event log — any GI, fatigue, mood, sleep, infection, neurologic.

Post-cycle

  • 2 weeks post-stop: Repeat cognitive battery vs. pre-cycle. Compare to baseline.
  • 4-6 weeks post-stop: Repeat NfL / GFAP if budget permits; the durable-improvement window in mouse models maps to this human timepoint roughly.
  • Annual review: Cumulative ISRIB exposure tally (track total mg-days). Hard cap: 2 cycles × 28 d in any 12-month window pending better long-term safety.
▸ Controversies / open debates Live debate
  • Calico / Praxis / AbbVie program failure interpretation. The HEALEY ALS Phase 2/3 fosigotifator failure (January 2025) and AbbVie-Calico partnership end (November 2025) are real signals. Two interpretations:
    • Bear: the eIF2B activator class doesn't work in human disease; mouse data overestimates effect; ISR suppression is too downstream / too late to fix neurodegeneration; ABBV's exit reflects internal data + commercial reality. (Note: AbbVie's stated rationale is also a strategic shift away from small molecules toward injectables and complex genetic medicines — not purely an ISRIB-program-killing data signal.)
    • Bull: ALS is a hard indication; trial endpoints (ALS-FRS-R, mortality) require massive effect sizes in a heterogeneous disease; modest secondary muscle-strength signals were positive; vanishing white matter (a more mechanism-direct indication) is still ongoing; trial design and timing may have been wrong, not the molecule. For TBI / cognition specifically — not the indication AbbVie tested — the failure is ambiguously informative.
    • My honest read: the failure substantially reduces enthusiasm for ISRIB-class as a daily-driver clinical compound for cognitive enhancement, but does not negate the preclinical TBI / aging memory-restoration data. The mechanism is real, the molecule works in mice, the human translation challenge is more about disease selection, dosing, formulation, and chronic safety than about whether the target is wrong.
  • Praxis Precision Medicines confusion. The user prompt mentioned "Praxis." For clarity: Praxis Precision Medicines (PRAX) is a separate company unrelated to ISRIB. Praxis develops CNS therapies in epilepsy and essential tremor; they have nothing to do with the ISRIB / eIF2B activator program. The relevant pharma history is UCSF (Walter lab discovery, 2013) → Calico (license, 2015, with Sidrauski joining) → Calico/AbbVie partnership (2014-2025) → fosigotifator (ABBV-CLS-7262) clinical development → HEALEY ALS Phase 2/3 failure (Jan 2025) → AbbVie exits Calico partnership (Nov 2025) → ISRIB program effectively orphaned. Denali Therapeutics has a separate eIF2B activator (DNL343) in development with different chemistry — that program may yet provide the next clinical readout for the class.
  • UPS impairment paradox. Cell biology (Nature Communications Biology 2024) showing chronic ISRIB impairs ubiquitin-proteasome clearance is a real concern, not a theoretical one. Counter-argument: in animal prion / DS / aged-brain models, ISRIB was protective and didn't accelerate aggregation pathology over the durations tested. Reconciliation: the time-scale matters. Short cycles (weeks) show benefit; chronic continuous suppression (months-years) may show paradoxical harm. Practical implication: short cycles only; never chronic daily.
  • Vendor identity / purity verification. ISRIB is a small molecule at the borderline of nootropic-vendor manufacturing competence. Cis vs. trans isomer distinction matters — only trans is fully active. COA verification is necessary, not paranoid.
  • Healthy-baseline use without ISR pathology to reverse. Mouse "healthy adult" 2013 data showed enhanced learning. Whether that translates to a healthy 20yo human with no detectable cognitive deficit is very underdetermined. The biologically-cleanest case is post-pathological-state (post-TBI, post-concussion, aged-brain). For preventive use in young healthy users, the case is mechanism-suggestive but evidence-weak.
  • Encyclopedia entry consistency check. The encyclopedia entry (NOOTROPICS-ENCYCLOPEDIA-2026-05-05.md, Section 29) describes drug-development as having "failed as of 2025" — accurate. It frames ISRIB as a "watch list" compound — also accurate. Flag: encyclopedia describes Cerebrolysin's TBI effect as "23% improvement" elsewhere and similar compact figures; ISRIB section is appropriately cautious without specific quantitative claims that would need verification.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: WATCH-LIST (MEDIUM confidence). ISRIB is the most mechanism-aligned compound for Dylan's MMA subconcussive-impact-recovery thesis, with A-tier preclinical TBI memory-restoration data replicated across multiple labs (Walter, Rosi, Costa-Mattioli, Mallucci, Sherman). Confidence is MEDIUM not HIGH because: (a) zero formal human efficacy trials of ISRIB itself; (b) only related Phase 2/3 readout (fosigotifator/ABBV-CLS-7262 in ALS) failed January 2025; (c) AbbVie ended the Calico partnership November 2025 leaving the development program effectively orphaned; (d) Nature Communications Biology 2024 showed chronic ISRIB impairs the ubiquitin-proteasome system — a real (not theoretical) chronic-use concern; (e) research-chem identity / purity verification is a meaningful operational hurdle; (f) Cerebrolysin + V4 baseline already covers the brain-protection thesis with much better evidence base. Action: WATCH-LIST. Defer any trial until (i) Dylan baseline bloodwork + 23andMe interpreted, (ii) first Cerebrolysin cycle completed and his neurotrophic-baseline established, (iii) any new clinical signal from DNL343 or successor eIF2B activators, OR (iv) Dylan takes a documented concussion and wants an aggressive evidence-stretched recovery stack. If trial happens: 5 mg oral × 14-28 d, paired with concurrent Cerebrolysin cycle, two-vendor identity verification, NfL/GFAP + cognitive battery pre/post, hard cap at 2 cycles per 12 months.
▸ Open questions / gaps Open
  1. Will any next-gen eIF2B activator clear human Phase 2 efficacy? DNL343 (Denali) is the most-watched successor. A positive readout would substantially upgrade the class verdict; another miss would push toward SKIP-FOR-NOW.
  2. Optimal post-concussion timing window in humans. Mouse data: weeks-to-months post-injury still benefit. Human equivalent: unknown. If Dylan ever needs this protocol, conservative assumption is start within 2-4 weeks.
  3. Oral bioavailability of bare ISRIB in humans. Almost certainly low (motivated the fosigotifator analog development), but no formal human PK published. Vendor-protocol oral doses (2.5-10 mg) may be substantially under-dosing brain exposure relative to mouse-IP-equivalent — or may be exactly enough; nobody knows.
  4. Intranasal route claimed by some vendors: mechanistically uncertain for a non-peptide small molecule; community anecdote only. No formal characterization.
  5. Long-term UPS / aggregation impact in humans. Nature Communications Biology 2024 data is cell-model. Whether this scales to clinical relevance in chronic dosing is unanswered. Conservative practice: never chronic.
  6. BDNF Val66Met / APOE / eIF2B variant pharmacogenomic moderation. All speculative. Worth checking on Dylan's 23andMe results when they land June 2026.
  7. Stack synergy with Cerebrolysin specifically. Mechanistically attractive (translation-restoration + neurotrophic surge) but zero direct combo data. If Dylan ever runs the post-concussion stack, his n=1 would be an interesting data point.
  8. Cumulative-cycle safety ceiling. Hard cap of 2 × 28-d cycles per 12 months is a conservative guess based on UPS concern; not derived from data.
▸ Sources (full, with our context)
Back to compact view